In 2027, Lithuania will take over the presidency of the European Union Council for the first half of the year, positioning the country at the center of European decision-making. This presidency will provide an exceptional platform for Lithuania to actively shape EU policies in health, economics, and security, while also making its voice heard regarding the future of the EU biotechnology sector. Approximately 200 events, including around 15 high-level meetings, are planned during this time, underscoring Lithuania's significant responsibility to set a direction that will impact the entire continent.

The groundwork for this ambitious agenda is already being laid, with the European Commission proposing various measures to bolster innovation in the life sciences sector. A key aspect of this effort is the proposed European Biotech Act, which aims to strengthen the biotechnology and biotech-based manufacturing sectors across the EU. This piece of legislation is expected to become regulatory, establishing a framework that will govern biotech initiatives within the Union and further encourage collaborative research and development.

As the European Parliament begins deliberations on this vital piece of legislation, Vytenis Povilas Andriukaitis has been entrusted with the responsibility of drafting a position on the matter. His role is crucial as it will help shape the legislative landscape for biotechnology in Europe, addressing the needs for innovation and collaboration within the sector while placing Lithuania at the forefront of these pivotal discussions.